Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Natera Inc (NTRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,144,510
  • Shares Outstanding, K 63,128
  • Annual Sales, $ 257,650 K
  • Annual Income, $ -128,150 K
  • 60-Month Beta 1.89
  • Price/Sales 4.54
  • Price/Cash Flow N/A
  • Price/Book 37.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.59
  • Number of Estimates 3
  • High Estimate -0.52
  • Low Estimate -0.65
  • Prior Year -0.61
  • Growth Rate Est. (year over year) +3.28%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.74 +2.17%
on 04/22/19
21.91 -17.25%
on 04/01/19
-1.55 (-7.88%)
since 03/22/19
3-Month
12.51 +44.92%
on 01/24/19
21.91 -17.25%
on 04/01/19
+4.15 (+29.69%)
since 01/22/19
52-Week
10.77 +68.34%
on 04/25/18
29.62 -38.79%
on 08/27/18
+7.17 (+65.42%)
since 04/20/18

Most Recent Stories

More News
Natera Announces Pricing of Follow-On Offering

Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA testing, today announced the pricing of its underwritten public offering of 5,263,158 shares of its common stock at a price to the public of...

NTRA : 18.13 (-2.21%)
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer

Molecular Residual Disease Detected Up to Two Years Prior to Clinical Relapse, with Zero False Positives

NTRA : 18.13 (-2.21%)
CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients

CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc. in the United...

NTRA : 18.13 (-2.21%)
CDNA : 25.78 (-2.72%)
Natera Announces Plans to Commercialize Tumor Whole Exome Sequencing from Plasma

Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for whole exome sequencing (WES) of circulating tumor DNA,...

NTRA : 18.13 (-2.21%)
Natera Inc Has Returned 38.1% Since SmarTrend Recommendation (NTRA)

SmarTrend identified an Uptrend for Natera Inc (NASDAQ:NTRA) on February 11th, 2019 at $14.87. In approximately 2 months, Natera Inc has returned 38.10% as of today's recent price of $20.54.

NTRA : 18.13 (-2.21%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Natera Inc (NTRA , ATRA , VCYT , ALKS , ALNY )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

VCYT : 23.02 (-0.04%)
NTRA : 18.13 (-2.21%)
ATRA : 31.69 (-0.53%)
Medicare Issues Draft Local Coverage Determination for Natera's New Prospera(TM) Kidney Transplant Rejection Test

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage determination (LCD) for use of the company's new Prospera donor-derived...

NTRA : 18.13 (-2.21%)
Analysis: Positioning to Benefit within JD, Five9, Ambarella, Natera, Methanex, and Virtusa -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of JD.com, Inc. (NASDAQ:JD), Five9,...

NTRA : 18.13 (-2.21%)
AMBA : 49.81 (+2.41%)
MEOH : 59.08 (+1.56%)
VRTU : 52.75 (+0.09%)
JD : 29.65 (-1.20%)
FIVN : 50.61 (+2.14%)
CareDx Files Patent Infringement Lawsuit Against Natera

CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant...

NTRA : 18.13 (-2.21%)
CDNA : 25.78 (-2.72%)
Natera to Partner with AMAL Therapeutics on Clinical Trial Using Signatera MRD Test to Assess Treatment Response to Colorectal Cancer Vaccine

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number...

NTRA : 18.13 (-2.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade NTRA with:

Business Summary

Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California.

See More

Key Turning Points

2nd Resistance Point 19.21
1st Resistance Point 18.67
Last Price 18.13
1st Support Level 17.67
2nd Support Level 17.20

See More

52-Week High 29.62
Fibonacci 61.8% 22.42
Fibonacci 50% 20.19
Last Price 18.13
Fibonacci 38.2% 17.97
52-Week Low 10.77

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar